Jonker M, Nooij F J, den Butter G, van Lambalgen R, Fuccello A J
Primate Center TNO, Rijswijk, The Netherlands.
Transplantation. 1988 Apr;45(4):677-82. doi: 10.1097/00007890-198804000-00002.
The immediate side effects of lymphocyte-specific monoclonal antibody treatment of nearly 150 monkeys is documented in this study. Immediate side effects were only seen with antibodies specific for CD3 and CD8. These side effects are most likely related to stimulation of T cells to produce lymphokines (CD3) and/or to the rapid cell clearance (CD3 and CD8). No immediate effects were observed when CD4 or major histocompatibility complex class II-specific antibodies were injected. These antibodies may therefore be considered for the treatment of graft rejection or autoimmune diseases. Of the 43 animals that received a monoclonal antibody (MoAb) at least 2 years and up to 5 years prior to this study, none has shown any late effects of MoAb treatment. Most animals tested had a vigorous immune response to the injected MoAbs, both antiidiotypic as well as anti-isotypic antibodies were formed. This response was reduced by using Fab2 fragments or by additional immunosuppression, but it was still high enough to prevent further effectiveness of the MoAb treatment.
本研究记录了近150只猴子接受淋巴细胞特异性单克隆抗体治疗后的即时副作用。仅在使用针对CD3和CD8的抗体时观察到即时副作用。这些副作用很可能与刺激T细胞产生淋巴因子（CD3）和/或快速清除细胞（CD3和CD8）有关。注射CD4或主要组织相容性复合体II类特异性抗体时未观察到即时效应。因此，这些抗体可考虑用于治疗移植排斥或自身免疫性疾病。在本研究前至少2年至5年接受单克隆抗体（MoAb）治疗的43只动物中，没有一只表现出MoAb治疗的任何后期效应。大多数受试动物对注射的MoAb有强烈的免疫反应，形成了抗独特型抗体以及抗同种型抗体。通过使用Fab2片段或额外的免疫抑制，这种反应有所降低，但仍足以阻止MoAb治疗的进一步有效性。
